摘要
目的:联合检测患者血清或腹水CA125和 CA19-9,以提高对肿瘤诊断与病情判断的准确性．方法:59例腹水患者以照良、恶性分为2 组．利用蛋白质芯片技术检测两组CA125和 CA19-9含量,并进行统计学分析．结果:恶性组腹水CA125和CA19-9分别为 602．03±405．72和370．65±490．01,均明显高于良性组,差异有显著性(P<0．01);恶性组血清CA125为213．30±251．36,与良性腹水组相比,没有显著性差异(P>0．05),而血清CA19-9 的测定值为65．80±117．45,显著高于良性腹水组(P<0．05)．CA19-9检测恶性腹水的特异性、敏感性和准确性分别为66．7％、46．2％、 57．7％;CA125的特异性、敏感性和准确性分别为57．6％、61．5％和59．3％;而联合检测腹水CA19-9和CA125的特异性、敏感性和准确性分别为57．6％、84．6％和69．5％,其中敏感性明显高于单独检测CA125(P<0．05)或CA19- 9(P<0．01)．结论:联合检测CA19-9和CA125诊断恶性腹水的敏感性和准确性可提高．
AIM： To investigate the significance of cancer antigen-125 （CA-125） and CA19-9 combined detection in the differential diagnosis of benign and malignant ascites.
METHODS： A total of 59 patients were included in the study and divided into two groups based on the benignancy and malignancy. The levels of CA-125 and CA19-9 were detected in serum and ascitic fluid by protein chip technique.
RESULTS： The levels of CA125 and CA19-9 in ascitic fluid were 602.03 ± 405.72 and 370.65 ± 490.01 in malignant group, which were significantly higher than those in benign group （P 〈0.05）. The level of serum CA125 was not markedly different between malignant and benign group, while CA19-9 level in malignant group （65.80 ± 117.45） was significantly higher than that in benign group （P 〈 0.05）. The specificity, sensitivity and accuracy of ascitic CA19-9 in the diagnosis of malignant diseases were 66.7%, 46.2%, 57.7%, and those of ascitic CA125 were 57.6%, 61.5% and 59.3%, respectively. The specificity, sensitivity and accuracy of combined detection of CA19-9 and CA125 were 57.6%, 84.6% and 69.5%, respectively, and the sensitivity was significantly higher than that of CA19-9 （P 〈 0.01） or CA125 （P 〈 0.05） alone.
CONCLUSION： It is helpful to detect ascitic CA19-9 combined with CA125 in the differential diagnosis of malignant diseases.
出处
《世界华人消化杂志》
CAS
北大核心
2006年第8期823-826,共4页
World Chinese Journal of Digestology
